NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics is a clinical-stage biotechnology company developing treatments for neurodegenerative diseases. The company is headquartered in Herzliya, Israel, and operates with a team of 17 full-time employees. As a pre-revenue entity, the company focuses on advancing its pipeline through clinical trials rather than generating commercial revenue streams.

The company's lead asset is PrimeC, an extended-release oral combination of ciprofloxacin and celecoxib. PrimeC is currently in Phase 2b/3 clinical trials for amyotrophic lateral sclerosis (ALS) and has completed Phase 2 trials for Alzheimer's disease, with preclinical evaluation underway for Parkinson's disease. The preclinical pipeline includes StabiliC and CogniC, both targeting neurodegenerative indications. NeuroSense was incorporated in 2017 and listed on Nasdaq, reflecting its status as a development-stage company pursuing U.S. and international markets for neurological treatments.